The pain level of patients in the different publications
is not mentioned. We know from clinical trial experience with tapentadol that patients had moderate to severe pain (most even severe pain [2, 3] ). The ER formulation of tapentadol would be the right one to use in the chronic condition osteoarthritis (OA). However, the high dosage shown in Table 1 indicates that this does not refer to tapentadol ER (according to the Summary of Product characteristics [SmPC] , the highest dosage recommended is 500 mg). The dosage mentioned in Table 1 seems to reflect the tapentadol IR dose for pricing purposes. This very high dosage leads to the unfavourably high result for tapentadol in the cost-effectiveness plane, which we cannot accept. 3. The dosing for oxycodone ER is not comparable with the dosing for tapentadol. Comparing the World Health Organization Defined Daily Dose (WHO-DDD), which is 400 mg for tapentadol and 75 mg for oxycodone, this would be a factor of 5.3 (which is also reflected in the clinical trials where oxycodone was used as active comparator [3] ). The very low dosage used for oxycodone (10-30 mg) would be suitable for patients with mild to moderate pain, whereas the dosage of 600 mg for tapentadol is beyond even that used in severe pain and therefore these are not comparable. 4. As a follow-up to the above, Table 1 Importantly, these data inaccuracies have led to very negative results for tapentadol, a strong opioid analgesic that was included in the study.
We respectfully would like to ask the journal to comment on these inaccuracies and their effects on the research results and conclusions. We would kindly ask that a revised analysis be conducted and/or that a correction/erratum be published in accordance with International Committee of Medical Journal Editors (ICMJE) requirements.
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